Show simple item record

dc.contributor.authorFernández-Delgado, Lucía
dc.contributor.authorCàmara, Jordi
dc.contributor.authorGonzález-Díaz, Aida
dc.contributor.authorGrau, Immaculada
dc.contributor.authorShoji, Hisashi
dc.contributor.authorTubau, Fe
dc.contributor.authorMartí, Sara
dc.contributor.authorDomínguez, Mª Ángeles
dc.contributor.authorCarratalà, Jordi
dc.contributor.authorYuste, Jose Enrique 
dc.contributor.authorArdanuy, Carmen
dc.identifier.citationMicroorganisms. 2021 Oct 28;9(11):2245.es_ES
dc.description.abstractWe studied changes in serotype distribution and antimicrobial susceptibility in adult pneumococcal pneumonia in Spain (2011-2019). Among 895 pneumococci collected (433 bacteremic [BPP] and 462 non-bacteremic [non-BPP]), serotypes 3 (17%), 19A (10%), 8 (6.7%) and 11A (6.7%) were the most frequent. Serotypes 16F, 19A and 24F were associated with old people (≥65) and serotypes 4, 7F, 8, 12F and 19F to young adults. Serotypes 12F, 24F and 1 were significantly more frequent in BPP and serotypes 11A, 23A and 19F in non-BPP. Amoxicillin resistance was higher in non-BPP (17% vs. 11%) while penicillin non-susceptibility (37% vs. 24%) and macrolide resistance (29% vs. 14%) were higher in older adults. In the period 2017-2019, the vaccine coverages were: 32% (PCV13), 39% (PCV15), 65% (PCV20) and 69% (PPV23). Differences were found in serotype composition and antimicrobial resistance by age and type of infection. The maintenance of serotype 3 as a leading cause of adult pneumococcal pneumonia and the increase in highly invasive (serotype 8) or antimicrobial-resistant (serotype 11A) serotypes is worrisome. Further studies will be required to analyse the impact of the upcoming broader conjugate vaccines.es_ES
dc.description.sponsorshipThis work was supported by grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social [PI (PI14/00627; PI18/00339, and by CIBER de Enfermedades Respiratorias, CIBERES; [CB06/06/0037], run by the Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Financial support was also provided by the European Regional Development Fund/European Social Fund (ERDF/ESF, “Investing in your future”). We thank CERCA Programme/Generalitat de Catalunya for institutional support.es_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectStreptococcus pneumoniaees_ES
dc.subjectAntimicrobial resistancees_ES
dc.subjectPneumococcal conjugate vaccines (PCVs)es_ES
dc.titleSerotypes in Adult Pneumococcal Pneumonia in Spain in the Era of Conjugate Vaccineses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderGovernment of Catalonia (España)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MSC//CB06%2F06%2F0037/ES/Enfermedades respiratorias 37/ es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2014). Modalidad proyectos en salud. (2014)/PI14/00627es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/00339es_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional